Plasmodium vivax the first-line treatment for "P. falciparum" malaria, it may also be used for P. vivax malaria in combination with primaquine for radical cure. An exception is artesunate plus sulfadoxine-pyrimethamine (AS+SP), which is not effective against P. vivax in many places. Mefloquine is a good alternative and in some countries is more readily available. Atovaquone-proguanil is an effective alternative in patients unable to tolerate chloroquine. Quinine may be used to treat "vivax" malaria but is associated with inferior outcomes. 32–100% of patients will relapse following successful treatment of "P. vivax" infection if a radical cure (eradication of liver stages) is not
Drugs for Neglected Diseases Initiative in 32 African countries, in India, Ecuador and in Colombia, and included in the WHO Model List of Essential Medicines. More than 437 million treatments had been distributed. A technology transfer agreement has been signed with industrial partner Zenufa in Tanzania in order to provide an additional source of ASAQ. ASAQ was handed over to the MMV Access and Product Management Team in May 2015. The second antimalarial treatment developed by DND"i" is a fixed-dose combination of artesunate and mefloquine launched in 2008. It was developed by an international collaboration within the FACT Project Consortium. It has a simple and